Showing 7681-7690 of 9819 results for "".
- Analysis Reveals Pre- and Post-COVID-19 Teledermatology Usage and Barriershttps://practicaldermatology.com/news/teledermatology-platforms-usage-and-barriers-a-cross-sectional-analysis-of-united-states-based-dermatologists-pre-and-post-covid-19/2462231/Dermatologists have increasingly turned to teledermatology to enhance patient care, but a recent study highlights crucial disparities in platform usage and functionality among practitioners. Researchers used cross-sectional pre-validated survey in 2021 and sought to discern va
- Benzoyl Peroxide 2.6% Cleanser Effective at Reducing Acne Lesionshttps://practicaldermatology.com/news/benzoyl-peroxide-26-cleanser-effective-at-reducing-acne-lesions/2462228/A benzoyl peroxide 2.6% (BPO) complexion clearing acne cleanser (CCAC) was effective at reducing acne, a new study reports.
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Navigating Antibiotic Use for Acne and Rosacea: Clinician Insights and Considerationshttps://practicaldermatology.com/news/navigating-antibiotic-use-for-acne-and-rosacea-clinician-insights-and-considerations/2462208/Growing apprehensions surrounding antibiotic resistance in acne and rosacea treatments, coupled with their linked
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://practicaldermatology.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled